63 / 64
REUNIÓN 6
55
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY
Steering Committee and Investigators. Dabigatran versus warfarin in patients with
atrial fibrillation. N Engl J Med. 2009;361:1139-51.
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al;
ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with
atrial fibrillation. N Engl J Med. 2011;365:981-92.
5. Schulman S, Shortt B, Robinson M, Eikelboom JW.Adherence to anticoagulant treat-
ment with dabigatran in a real-world setting. J Thromb Haemost. 2013;11:1295-9.
6. ClinicalTrials.gov. Dabigatran Adherence Study. Disponible en:
http://www.clinical-
trials.gov/ct2/show/NCT01578044?term=dabigatran+adherence+study&rank=1
7. Ficha tecnica de Xarelto (rivaroxabán). Julio 2014.
http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000944/
WC500057108.pdf
8. Ficha técnica de Pradaxa (dabigatrán). Junio 2014.
http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000829/
WC500041059.pdf
9. Ficha técnica de Eliquis (apixabán). Julio de 2014.
http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002148/
WC500107728.pdf
10. Lefkovitz A, Zarowitz B. Top 10 lists - medications associated with adverse events
and medications involved with errors. Geriatr Nurs. 2007;28:276-9.